MTHFR C677T and MTR A2756G polymorphisms and the homocysteine lowering efficacy of different doses of folic acid in hypertensive Chinese adults.
Xianhui Qin, Jianping Li, Yimin Cui...
https://pubmed.ncbi.nlm.nih.gov/22230384/Actively Recruiting
Led by Shenzhen Ausa Pharmed Co.,Ltd · Updated on 2025-02-26
32000
Participants Needed
20
Research Sites
N/A
Total Duration
Researchers are investigating the effects of amlodipine alone versus amlodipine combined with folic acid in Chinese adults aged 45 to 74 years who have H-type hypertension, specific MTHFR 677 genotypes CC or CT, elevated plasma homocysteine levels, and low serum folate. This large, multi-center, randomized, double-blind, double-dummy clinical trial aims to evaluate which treatment better reduces the risk of first ischemic stroke over five years. Participants are first screened and then enter a 2 to 4 week run-in period where they take amlodipine to assess tolerance and compliance. Afterward, eligible participants are randomized by genotype into two groups one receiving amlodipine 5mg daily with a placebo, and the other receiving amlodipine 5mg combined with 0.8mg folic acid daily with a placebo. Other blood pressure medications may be added as needed to reach target blood pressure goals. Follow-up visits occur every three months during the five-year treatment period with medication provided at each visit. Throughout the study, participants undergo interviews, clinical evaluations, and laboratory tests including genetic and blood analyses. Researchers monitor adherence, blood pressure, and cardiovascular health. The main outcome measured is the occurrence of first ischemic stroke by the end of five years. Secondary outcomes include other cardiovascular events and kidney function. Two interim analyses will be conducted during the study to assess progress and safety.
CONDITIONS
China Stroke Primary Prevention Trial 2 for Participants With H-type Hypertension and MTHFR 677 CC/CT Genotype (CSPPT2-CC/CT)
M
Minqing Tian, PhD
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here
Shenzhen Ausa Pharmed Co.,Ltd
Lead Sponsor
Peking University First Hospital
Collaborating Sponsor
You may qualify if you...
You will not qualify if you...
Duration - 2 to 4 weeks
Participants are screened for eligibility to participate in the trial.
1 visit (in-person)
Duration - 2 to 4 weeks
Participants take amlodipine once daily to assess tolerance and compliance before randomization.
1 visit during run-in
Duration - Up to 5 years
Participants are randomly assigned to receive either amlodipine only or amlodipine with folic acid daily, with follow-up visits every 3 months to monitor treatment and adjust medications as needed.
Quarterly visits every 3 months during treatment
Study Type
INTERVENTIONAL
Masking
QUADRUPLE
Allocation
RANDOMIZED
Model
PARALLEL
Primary Purpose
TREATMENT
Number of Arms
4
Have more questions? Get in touch with our team for quick support
Xianhui Qin, Jianping Li, Yimin Cui...
https://pubmed.ncbi.nlm.nih.gov/22230384/Xianhui Qin, Youbao Li, Ningling Sun...
https://pubmed.ncbi.nlm.nih.gov/27834686/Xianhui Qin, Jianping Li, Yimin Cui...
https://pubmed.ncbi.nlm.nih.gov/21869730/Xiao Huang, Youbao Li, Ping Li...
https://pubmed.ncbi.nlm.nih.gov/29030456/B Wilcken, F Bamforth, Z Li...
https://pubmed.ncbi.nlm.nih.gov/12920077/Qing Dong, Genfu Tang, Mingli He...
https://pubmed.ncbi.nlm.nih.gov/22897803/Xiaowei Xu, Jiejie Li, Wenli Sheng...
https://pubmed.ncbi.nlm.nih.gov/18511872/Homocysteine Lowering Trialists’ Collaboration
https://pubmed.ncbi.nlm.nih.gov/9569395/Xianhui Qin, Jianping Li, Yan Zhang...
https://pubmed.ncbi.nlm.nih.gov/22880024/Homocysteine Lowering Trialists' Collaboration
https://pubmed.ncbi.nlm.nih.gov/16210710/Shenzhen Ausa Pharmed Co.,Ltd
Lead Sponsor
Peking University First Hospital
Collaborating Sponsor